Marina Biotech, Inc. Announces That Licensee Mirna Therapeutics, Inc. Reported Initiation of a Phase 1 Clinical Trial of Anticancer Drug MRX34
5/13/2013 11:48:23 AM
More...
|
Mirna Therapeutics, Inc. is First to Advance MicroRNA into the Clinic for Cancer
5/13/2013 10:28:20 AM
More...
|
Mirna Therapeutics, Inc. Appoints Clay B. Siegall, Ph.D., to its Board of Directors
1/30/2013 8:23:40 AM
More...
|
Mirna Therapeutics, Inc. Presents Preclinical Data on Lead Product Candidate MRX34 at Keystone Conference
1/23/2013 9:37:31 AM
More...
|
Mirna Therapeutics, Inc. Secures $34.5 Million Series C Financing
10/24/2012 7:29:55 AM
More...
|
Mirna Therapeutics, Inc. Presents Updates on Development Program for Lead Therapeutic Candidate
5/22/2012 11:23:04 AM
More...
|
Mirna Therapeutics, Inc. Publishes Preclinical Data Demonstrating Therapeutic Effects of microRNA in Hematological Cancer
5/2/2012 10:09:56 AM
More...
|
Mirna Therapeutics, Inc. to Present at Biotech Showcase™ 2012
1/5/2012 7:40:20 AM
More...
|
Marina Biotech, Inc. (Formerly Known as MDRNA, Inc.) and Mirna Therapeutics, Inc. Announce License Agreement for Up to $63 Million for the Development of microRNA-Based Therapeutics
12/28/2011 7:01:54 AM
More...
|
Mirna Therapeutics, Inc. Presents New Data on the Development of miRNA-based Therapeutic Candidates for Hepatocellular Carcinoma
11/15/2011 6:58:17 AM
More...
|
|